

September 7, 2020

Company Name: CellSeed Inc. (TSE 7776)  
Representative: Setsuko Hashimoto, President and CEO  
Contact: Jun Onodera, CFO and Board Director  
Telephone: +81 3-6380-7490

## **Announcement of the starting of the supply of the cell cultureware to the company, developing the cells for research of the infectious disease**

We are pleased to announce that we have started to supply the cell cultureware (hereinafter referred to as the "Cultureware") to MiCAN Technologies Inc. which develops and sells the cells for the research of the various infectious diseases including new coronavirus infectious diseases (hereinafter referred to as the "COVID-19 ") and immune system diseases.

### **1. Transaction**

At present, the COVID-19 continues to spread world-wide and early development of effective vaccines is desired.

Our business partner, MiCAN Technologies Inc. is promoting development and sale of the cells for research to elucidate the mechanism of various viral infectious diseases including COVID 19 and immune system diseases which are used to develop medicine. And MiCAN Technologies was awarded the grant for the project "Cell development for evaluation of ADE in vaccine development for COVID-19 ". The grant called "Technology development project for measures against infectious diseases such as viruses", which was publicly recruited by Japan Agency for Medical Research and Development (AMED).

As stated above, we are about to supply the Cultureware as a component of their products, which will be manufactured and sold by MiCAN.

We are very proud that we can contribute to the tasks to overcome various diseases such as COVID-19 by providing our Cultureware.

### **2. Overview of MiCAN Technologies Inc.**

Company establishment: July 7, 2016

First investee of OUVC fund operated by Osaka University Venture Capital

Business: Develop and sell the immature red blood-like cells products for research produced with regenerative medicine technologies

Address: KKVP, 1-36 Goryo-ohara, Nishikyo-ku, Kyoto 615-8245 Japan

President and CEO: Kazuo Miyazaki

### **3. Impact on business performance**

The impact of this matter on our business results for the current fiscal year will be minor at the moment. if it will be a significant impact on our business performance, we will announce it as soon as possible.